???global.info.a_carregar???
Diogo Gomes-Silva completed his PhD in Bioengineering- Cell Therapy and Regenerative Medicine in 2018 by University of Lisbon, Instituto Superior Técnico, a Master in Biomedical Research by University of Coimbra, Faculdade of Medicine and a Licenciatura (Bachelor) in Genetics and Biotechnology by University of Trás-os-Montes e Alto Douro. During his PhD program he received extensive training in CAR T cell therapies at Baylor College of Medicine in Houston at Dr Malcolm K Brenner’ lab, a worldwide pioneer in cell therapy. In the last years his work has consisted in preclinical validation of genetically modified T cells as therapy for different hematologic tumors with published articles in scientific journals on this subject. He is now developing new CAR T cell therapies at Gulbenkian Institute for Molecular Medicine (former Institute of Molecular Medicine)
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Diogo Silva

Nomes de citação

  • Gomes-Silva, Diogo

Identificadores de autor

Ciência ID
4713-8A8A-C69D
ORCID iD
0000-0002-9615-3735

Endereços de correio eletrónico

  • diogo.silva@gimm.pt (Profissional)

Moradas

  • Instituto de Medicina Molecular João Lobo Antunes, Avenida Professor Egas Moniz, 1649-028, Lisboa, Lisboa, Portugal (Profissional)

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Biotecnologia Médica - Tecnologias que envolvem a Manipulação de Células,Tecidos,Órgãos ou todo o Organismo
  • Ciências Médicas e da Saúde - Medicina Clínica - Oncologia

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Português (Idioma materno)
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Formação
Grau Classificação
2014/04 - 2018/10
Concluído
 Bioengineering-Cell Therapies and Regenerative Medicine (Doutoramento)
Especialização em Terapias Celulares e Medicina Regenerativa
Universidade de Lisboa Instituto Superior Técnico, Portugal
"Engineering of T cells with Chimeric Antigen Receptors as a Therapy for Hematologic Cancers" (TESE/DISSERTAÇÃO)
 Approved with distinction
2010/09 - 2012/12
Concluído
 Biomedical Research (Mestrado)
Universidade de Coimbra Faculdade de Medicina, Portugal
"Alterations of Natural Killer cells according to reactive oxygen species production" (TESE/DISSERTAÇÃO)
 17
2006/09 - 2009/06
Concluído
 Genetics and Biotechnology (Licenciatura)
Universidade de Trás-os-Montes e Alto Douro Escola de Ciências da Vida e do Ambiente, Portugal
"Analysis of genetic variability of Sambucus nigra L. using ISSRs" (TESE/DISSERTAÇÃO)
 15
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2024/10/01 - Atual Pós-doutorado (Investigação) Gulbenkian Institute for Molecular Medicine, Portugal
2020/01/15 - 2024/07/31 Pós-doutorado (Investigação) Instituto de Medicina Molecular, Portugal
2018/10/18 - 2019/10/31 Pós-doutorado (Investigação) Universidade de Lisboa Instituto Superior Técnico, Portugal
Universidade de Lisboa Instituto Superior Técnico, Portugal
2015/06/01 - 2017/12/18 Investigador visitante (Investigação) Baylor College of Medicine Center for Cell and Gene Therapy, Estados Unidos
2013/01/01 - 2014/02/28 Estagiário de Investigação (Investigação) Universidade de Coimbra, Portugal
Projetos

Bolsa

Designação Financiadores
2025/02/01 - 2026/07/31 Development of a Chimeric Antigen Receptor T cell therapy against oncologic-glycans
2023.13874.PEX
Investigador responsável
Fundação para a Ciência e a Tecnologia, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2023/10/01 - 2025/10/31 Development of a Chimeric Antigen Receptor T cell therapy against oncologic-specific glycans
21727
Investigador responsável
Instituto de Medicina Molecular, Portugal
 Gilead Sciences Lda
Em curso
2022/04/01 - 2024/03/31 Development of a Chimeric Antigen Receptor T cell therapy targeting oncological-associated chondroitin sulfate as cancer treatment
TF 2022-24 DS
Investigador responsável
Instituto de Medicina Molecular, Portugal
 Liga Portuguesa Contra o Cancro

Terry Fox Foundation
Concluído
2021/01/01 - 2022/12/31 Development of a novel chimeric antigen receptor T cell therapy using B-cell activating factor, for triple targeting of B-cell specific receptors for multiple myeloma and other mature B cell neoplasms
Investigador responsável
Instituto de Medicina Molecular, Portugal
 Associação Portuguesa Contra a Leucemia

Sociedade Portuguesa de Hematologia
Concluído

Projeto

Designação Financiadores
2023/03/01 - 2029/02/28 Targeting of oncologic-specific chondroitin sulfate by a novel chimeric antigen receptor T cell therapy
2022.08489.CEECIND
Investigador Pós-doutorado
Instituto de Medicina Molecular, Portugal
 Fundação para a Ciência e a Tecnologia
Em curso
2020/04/01 - 2022/12/31 Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by infusion of purified allogeneic donor regulatory T lymphocytes
iMM/BIPD/3-2020
Bolseiro de Pós-Doutoramento
Institute of Molecular Medicine, Portugal
 Horizon 2020
Concluído

Outro

Designação Financiadores
2019/01/01 - 2019/12/31 Institute for Bioengineering and Biosciences
UID/BIO/04565/2019
Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, Portugal

Universidade de Lisboa Instituto de Bioengenharia e Biociências, Portugal
Fundação para a Ciência e a Tecnologia
Concluído
Produções

Publicações

Artigo em revista
  1. Feiyan Mo; Norihiro Watanabe; Mary K. McKenna; M. John Hicks; Madhuwanti Srinivasan; Diogo Gomes-Silva; Erden Atilla; et al. "Engineered off-the-shelf therapeutic T cells resist host immune rejection". Nature Biotechnology 39 1 (2021): 56-63. https://doi.org/10.1038/s41587-020-0601-5.
    10.1038/s41587-020-0601-5
  2. Gomes-Silva, Diogo; Atilla, Erden ; Atilla, Pinar Ataca ; Mo, Feiyan; Tashiro, Haruko; Srinivasan, Madhuwanti; Lulla, Premal; et al. "CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia". Molecular Therapy 27 1 (2019): 272-280. https://doi.org/10.1016%2Fj.ymthe.2018.10.001.
    10.1016/j.ymthe.2018.10.001
  3. Gomes-Silva, Diogo; Ramos, Carlos A.. "Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line". Biotechnology Journal 13 2 (2018): 1700097-1700097. https://doi.org/10.1002/biot.201700097.
    10.1002/biot.201700097
  4. Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti; Sharma, Sandhya; Gomes-Silva, Diogo; Mo, Feiyan; Krenciute, Giedre; Orange, Jordan S.; Brenner, Malcolm K.. "Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies". Cancer Immunology Research 6 1 (2017): 47-58. http://dx.doi.org/10.1158/2326-6066.cir-17-0126.
    10.1158/2326-6066.cir-17-0126
  5. Gomes-Silva, Diogo; Mukherjee, Malini; Srinivasan, Madhuwanti; Krenciute, Giedre; Dakhova, Olga; Zheng, Yueting; Cabral, Joaquim M.S.; et al. "Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent". Cell Reports 21 1 (2017): 17-26. http://dx.doi.org/10.1016/j.celrep.2017.09.015.
    10.1016/j.celrep.2017.09.015
  6. Gomes-Silva, Diogo; Srinivasan, Madhuwanti; Sharma, Sandhya; Lee, Ciaran M. ; Wagner, Dimitrios L.; Davis, Timothy H. ; Rouce, Rayne; et al. "CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies". Blood 130 3 (2017): 285-296. https://doi.org/10.1182/blood-2017-01-761320.
    10.1182/blood-2017-01-761320
Poster em conferência
  1. Silva, Diogo; Tashiro, Haruko; Sharma, Sandhya; Srinivasan, Madhuwanti; Rouce, Rayne; Lulla, Premal; Ramos, Carlos A. ; Brenner, Malcolm K.; Mamonkin, Maksim. "Non-myeloablative CAR T Cell Therapy for Acute Myeloid Leukemia". Trabalho apresentado em American Society of Hematology Annual Meeting, 2017.
  2. Gomes-Silva, Diogo; Tashiro, Haruko; Srinivasan, Madhuwanti; Rouce, Rayne; Lulla, Premal; Ramos, Carlos; Brenner, Malcolm K.; Mamonkin, Maksim. "Preclinical Development of CD7 CAR T Cells for the Treatment of Acute Myeloid Leukemia". Trabalho apresentado em American Society Of Gene And Cell therapy Annual Meeting, 2017.
  3. Gomes-Silva, Diogo; Tashiro, Haruko; Srinivasan, Madhuwanti; Rouce, Rayne; Lulla, Premal; Ramos, Carlos; Brenner, Malcolm K.; Mamonkin, Maksim. "CD7 CAR T cells for the Treatment of T-ALL and AML". Trabalho apresentado em American Society of Hematology Annual Meeting, 2016.
  4. Gomes-Silva, Diogo; Mukherjee, Malini; Srinivasan, Madhuwanti; Orange, Jordan S.; Brenner, Malcolm K.; Mamonkin, Maksim. "Tonic 4-1BB signaling induces apoptosis and impairs function of CD19 CAR T cells". Trabalho apresentado em American Society Of Gene And Cell therapy Annual Meeting, 2016.
  5. Gomes-Silva, Diogo. "Increase of Reactive Oxygen Species in Natural Killer cells from Pulmonary Tuberculosis patients". Trabalho apresentado em 15th International Congress of Immunology (ICI), 2013.
    10.3389/conf.fimmu.2013.02.00533
  6. Gomes-Silva, Diogo. "IL-15 IL-2, IL-12 and IL-15 prevent reactive oxygen species accumulation on natural killer cells from Chronic Myeloid Leukemia patients following interferon-alpha, imatinib and dasatinib therapy". Trabalho apresentado em 18th Congress of the European Hematology Association, 2013.
  7. Gomes-Silva, Diogo. "Screening of ABL kinase domain mutations using next generation sequencing in Chronic Myeloid Leukemia: impact in the response to treatment with tyrosine kinase inhibitors". Trabalho apresentado em European School of Hematology - iCMLf International Conference on CML- Biology and Therapy, 2012.
Resumo em conferência
  1. Atilla, Pinar Ataca ; Atilla, Erden; Tashiro, Haruko; Srinivasan, Madhuwanti; Gomes-Silva, Diogo; Mamonkin, Maksim; Brenner, Malcolm K.. "Optimizing C-Type Lectin-like Molecule 1 (CLL-1) Directed CAR T Cell Therapy of Acute Myeloid Leukemia". 2019.
    10.1016/j.bbmt.2018.12.470
  2. Gomes da Silva, D; Mukherjee, M.; Madhuwanti, S.; Dakhova, O.; Liu, H.; Grilley, B.; Gee, A.; et al. "Direct comparison of in vivo fate of second and third-generation CD19-specific chimeric antigen receptor (CAR)-T cells in patients with b cell non-hodgkin lymphoma (B-NHL): Reversal of toxicity from tonic signaling". 2017.
    10.1016/j.jcyt.2017.02.010
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2022/10/18 CAR T Cells- from science to the clinic Rede Saúde: Workshop Perspetivas Atuais e Futuras para a Investigação e Adoção de Terapias Celulares
University of Lisbon (Lisbon, Portugal)
2019 Immunology in the context of CAR T cells Annual Meeting for Young Hematologists
Portuguese Society of Hematology (Porto, Portugal)
2018/06/29 Tonic 4-1BB Costimulation in chimeric antigen receptors impedes T cell cytotoxicity and survival and is vector-dependent SPI (Portuguese Immunology Society) Annual Meeting
Portuguese Immunology Society (Lisboa, Portugal)
2018/06/27 CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia 25th Porto Cancer meeting - Cancer Wars: The Immune Force Awakens
i3S- Instituto de Investigação e Inovação em Saúde (Porto, Portugal)
2018/04/27 CD7-Edited T Cells Expressing a CD7-Specific Chimeric Antigen Receptor for the Therapy of Acute Myeloid Leukemia XXV Porto Cancer Meeting
i3S Institute for Research and Innovation in Health (Porto, Portugal)
2017/05/11 Genome Editing Enables Generation of CD7 CAR T cells for the Therapy of T-cell Malignancies American Society of Gene and Cell Therapy Annual Meeting
American Society of Gene and Cell Therapy (Washington, Estados Unidos)

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2022/11/23 - Atual Invited speaker in the seminar "Cancer Immunoterapy" organized for the students of Bachelor of Medicinal Chemistry at University of Coimbra, Portugal.
Seminário
Universidade de Coimbra, Portugal
2024/02/28 - 2024/02/28 Invited speaker to lecture about adoptive cell therapies - CAR T cells in the immuno-oncology course to medical students from Faculty of Medicine of Lisbon University immuno-oncology
Universidade de Lisboa Faculdade de Medicina, Portugal
2023/03/15 - 2023/03/15 Invited speaker to lecture about adoptive cell therapies - CAR T cells to students from Oncobiology Master at Faculty of Medicine of Lisbon University Master in Oncobiology
Universidade de Lisboa Faculdade de Medicina, Portugal
2023/02/22 - 2023/02/22 Invited speaker to lecture about adoptive cell therapies - CAR T cells in the immuno-oncology course to medical students from Faculty of Medicine of Lisbon University immuno-oncology
Universidade de Lisboa Faculdade de Medicina, Portugal

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2022/02/22 - 2022/02/22 Adoptive cell therapies- CAR T cells Medicina (Mestrado integrado) Universidade de Lisboa Faculdade de Medicina, Portugal

Membro de associação

Nome da associação Tipo de participação
2016/01/17 - 2024/03/26 American Society of Gene and Cell Therapy Associate Member- designed for individuals who are postdoctoral fellows, undergraduate or graduate students, in gene and cell therapy research programs

Outro júri / avaliação

Descrição da atividade Instituição / Organização
2020 - Atual Peer review of the manuscript "Demonstrating the Manufacture of Human CAR-T Cells in an Automated Stirred-tank Bioreactor" published by Biotechnology Journal https://doi.org/10.1002/biot.202000177
2019/06/10 - 2019/07/24 Peer review of "Mass Production of Highly Active NK Cells for Cancer Immunotherapy in a GMP Conform Perfusion Bioreactor", published in Frontiers in Frontiers in Bioengineering and Biotechnology ISSN 2296-4185 (link: https://www.frontiersin.org/articles/10.3389/fbioe.2019.00194/full)

Tutoria

Tópico Nome do aluno
2023/10/01 - 2024/07/31 Development of a Chimeric Antigen Receptor T cell therapy against oncologic-specific glycans Miguel Gonçales Carneiro de Moura
Distinções

Prémio

2018 Best Oral Presentation at SPI annual meeting
Sociedade Portuguesa de Imunologia, Portugal
2017 Outstanding Poster Presentation Award at 20th ASGCT Annual Meeting
American Society of Gene and Cell Therapy, Estados Unidos
2017 Meritorious Abstract Travel Award for 20th ASGCT Annual Meeting
American Society of Gene and Cell Therapy, Estados Unidos
2016 Outstanding Poster Presentation Award at 19th ASGCT Annual Meeting
American Society of Gene and Cell Therapy, Estados Unidos